Listed

Korro Bio, Inc.

KRRONasdaqCIK 1703647HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$0Revenue, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001193125-26-336707.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 6, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$0Revenue, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001193125-26-336707.Report this figureSign changed from a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating marginnot reported (Revenue of zero not reported)No year-earlier figure to compare
  • Net marginnot reported (Revenue of zero not reported)No year-earlier figure to compare
  • Diluted EPS−$1.07Diluted EPS, Q2 FY2026, three months to 2026-06-30−$1.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001193125-26-336707.Report this figure+60.9% on a year earlier
  • Free cash flow−$17.0mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$17.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001193125-26-336707. Derived: 6-month figure less the 3-month figure.Capital expenditure: $37.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001193125-26-336707. Derived: 6-month figure less the 3-month figure.Report this figure+12.1% on a year earlier

Last eight quarters

Full statements
Revenue$0Operating margin not reported
Diluted EPS−$1.07, Q2 FY2026
Free cash flow−$17.0m, Q2 FY2026
Korro Bio, Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m0.0Revenue, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-12, accession 0001193125-25-277572.Report this figure2.3Revenue, Q4 FY2024, three months to 2024-12-31$2.3m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-12, accession 0001193125-26-104156. Derived: 12-month figure less the 9-month figure.Report this figure2.6Revenue, Q1 FY2025, three months to 2025-03-31$2.5m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-07, accession 0001193125-26-210303.Report this figure1.5Revenue, Q2 FY2025, three months to 2025-06-30$1.5m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001193125-26-336707.Report this figure1.1Revenue, Q3 FY2025, three months to 2025-09-30$1.1m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-12, accession 0001193125-25-277572.Report this figure1.3Revenue, Q4 FY2025, three months to 2025-12-31$1.3m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-12, accession 0001193125-26-104156. Derived: 12-month figure less the 9-month figure.Report this figure0.0Revenue, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-07, accession 0001193125-26-210303.Report this figure0.0Revenue, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001193125-26-336707.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%not reported (Revenue of zero not reported)(1014.5%)Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: −$23.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-12, accession 0001193125-26-104156. Derived: 12-month figure less the 9-month figure.Revenue: $2.3m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-12, accession 0001193125-26-104156. Derived: 12-month figure less the 9-month figure.Report this figure(981.2%)Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$25.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001193125-26-210303.Revenue: $2.5m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-07, accession 0001193125-26-210303.Report this figure(1863.2%)Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$27.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-336707.Revenue: $1.5m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001193125-26-336707.Report this figure(1764.9%)Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: −$19.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-277572.Revenue: $1.1m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-12, accession 0001193125-25-277572.Report this figure(3900.6%)Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: −$50.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-12, accession 0001193125-26-104156. Derived: 12-month figure less the 9-month figure.Revenue: $1.3m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-12, accession 0001193125-26-104156. Derived: 12-month figure less the 9-month figure.Report this figurenot reported (Revenue of zero not reported)not reported (Revenue of zero not reported)
Net margin%not reported (Revenue of zero not reported)(933.5%)Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: −$21.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-12, accession 0001193125-26-104156. Derived: 12-month figure less the 9-month figure.Revenue: $2.3m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-12, accession 0001193125-26-104156. Derived: 12-month figure less the 9-month figure.Report this figure(917.1%)Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: −$23.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-336707.Revenue: $2.5m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-07, accession 0001193125-26-210303.Report this figure(1765.1%)Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: −$25.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-336707.Revenue: $1.5m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-06, accession 0001193125-26-336707.Report this figure(1657.0%)Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: −$18.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-277572.Revenue: $1.1m. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-12, accession 0001193125-25-277572.Report this figure(3873.2%)Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: −$50.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-12, accession 0001193125-26-104156. Derived: 12-month figure less the 9-month figure.Revenue: $1.3m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-12, accession 0001193125-26-104156. Derived: 12-month figure less the 9-month figure.Report this figurenot reported (Revenue of zero not reported)not reported (Revenue of zero not reported)
Diluted EPS$ per share(2.26)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$2.26 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001193125-25-277572.Report this figurenot reported (Diluted EPS not reported)(2.49)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$2.49 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001193125-26-210303.Report this figure(2.74)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$2.74 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001193125-26-336707.Report this figure(1.92)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$1.92 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001193125-25-277572.Report this figurenot reported (Diluted EPS not reported)(1.69)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$1.69 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001193125-26-210303.Report this figure(1.07)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$1.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001193125-26-336707.Report this figure
Free cash flow$m(21.0)Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$16.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001193125-25-277572. Derived: 9-month figure less the 6-month figure.Capital expenditure: $4.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-12, accession 0001193125-25-277572. Derived: 9-month figure less the 6-month figure.Report this figure(8.9)Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$7.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-12, accession 0001193125-26-104156. Derived: 12-month figure less the 9-month figure.Capital expenditure: $1.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-12, accession 0001193125-26-104156. Derived: 12-month figure less the 9-month figure.Report this figure(24.6)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$24.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001193125-26-210303.Capital expenditure: $119.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001193125-26-210303.Report this figure(19.4)Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$19.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001193125-26-336707. Derived: 6-month figure less the 3-month figure.Capital expenditure: $140.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001193125-26-336707. Derived: 6-month figure less the 3-month figure.Report this figure(17.4)Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: −$17.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001193125-25-277572. Derived: 9-month figure less the 6-month figure.Capital expenditure: $175.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-12, accession 0001193125-25-277572. Derived: 9-month figure less the 6-month figure.Report this figure(17.8)Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$17.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-12, accession 0001193125-26-104156. Derived: 12-month figure less the 9-month figure.Capital expenditure: $84.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-12, accession 0001193125-26-104156. Derived: 12-month figure less the 9-month figure.Report this figure(16.1)Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$16.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001193125-26-210303.Capital expenditure: $21.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001193125-26-210303.Report this figure(17.0)Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$17.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001193125-26-336707. Derived: 6-month figure less the 3-month figure.Capital expenditure: $37.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001193125-26-336707. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$6.4mOperating margin −1906.4%
Diluted EPS−$12.48, FY2025
Free cash flow−$79.1m, FY2025
Korro Bio, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m14.1Revenue, FY2021, twelve months to 2021-12-31$14.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-03-10, accession 0000950170-23-007140.Report this figure0.0Revenue, FY2022, twelve months to 2022-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-03-10, accession 0000950170-23-007140.Report this figure0.0Revenue, FY2023, twelve months to 2023-12-31$0. XBRL concept us-gaap:Revenues. 10-K filed 2025-03-18, accession 0000950170-25-040759.Report this figure2.3Revenue, FY2024, twelve months to 2024-12-31$2.3m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-12, accession 0001193125-26-104156.Report this figure6.4Revenue, FY2025, twelve months to 2025-12-31$6.4m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-12, accession 0001193125-26-104156.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(597.3%)Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: −$84.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2023-03-10, accession 0000950170-23-007140.Revenue: $14.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-03-10, accession 0000950170-23-007140.Report this figurenot reported (Revenue of zero not reported)not reported (Revenue of zero not reported)(4047.1%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$91.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-12, accession 0001193125-26-104156.Revenue: $2.3m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-12, accession 0001193125-26-104156.Report this figure(1906.4%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$121.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-12, accession 0001193125-26-104156.Revenue: $6.4m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-12, accession 0001193125-26-104156.Report this figure
Net margin%(602.0%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −$84.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2023-03-10, accession 0000950170-23-007140.Revenue: $14.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2023-03-10, accession 0000950170-23-007140.Report this figurenot reported (Revenue of zero not reported)not reported (Revenue of zero not reported)(3680.4%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$83.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-12, accession 0001193125-26-104156.Revenue: $2.3m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-12, accession 0001193125-26-104156.Report this figure(1834.5%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −$117.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-12, accession 0001193125-26-104156.Revenue: $6.4m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-12, accession 0001193125-26-104156.Report this figure
Diluted EPS$ per share(2.47)Diluted EPS, FY2021, twelve months to 2021-12-31−$2.47 per share. XBRL concept us-gaap:EarningsPerShareBasicAndDiluted. 10-K filed 2022-03-15, accession 0000950170-22-003655.Report this figure(227.42)Diluted EPS, FY2022, twelve months to 2022-12-31−$227.42 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-03-26, accession 0000950170-24-036396.Report this figure(53.08)Diluted EPS, FY2023, twelve months to 2023-12-31−$53.08 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-18, accession 0000950170-25-040759.Report this figure(9.37)Diluted EPS, FY2024, twelve months to 2024-12-31−$9.37 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-12, accession 0001193125-26-104156.Report this figure(12.48)Diluted EPS, FY2025, twelve months to 2025-12-31−$12.48 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-12, accession 0001193125-26-104156.Report this figure
Free cash flow$m(79.0)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −$76.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-03-10, accession 0000950170-23-007140.Capital expenditure: $2.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-03-10, accession 0000950170-23-007140.Report this figure(58.8)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$53.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-03-26, accession 0000950170-24-036396.Capital expenditure: $5.1m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-03-26, accession 0000950170-24-036396.Report this figure(75.1)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$67.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-18, accession 0000950170-25-040759.Capital expenditure: $7.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-18, accession 0000950170-25-040759.Report this figure(78.0)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$60.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-12, accession 0001193125-26-104156.Capital expenditure: $17.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-12, accession 0001193125-26-104156.Report this figure(79.1)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$78.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-12, accession 0001193125-26-104156.Capital expenditure: $518.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-12, accession 0001193125-26-104156.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

By month, by reported value, last 24 monthsPurchases $884.8kSales $0
Korro Bio, Inc., open-market insider transactions
DateInsiderTransactionSharesReported priceValueFiling
2026-10-26Lynx1 Capital Management LP10% owner Purchase25,124$11.7454$295.1kForm 4
2026-10-23Lynx1 Capital Management LP10% owner Purchase2,510$12.1061$30.4kForm 4
2026-10-22Lynx1 Capital Management LP10% owner Purchase40,000$11.0366$441.5kForm 4
2026-10-22Lynx1 Capital Management LP10% owner Purchase12,175$9.6764$117.8kForm 4

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Korro Bio, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
Lynx1 Capital Management LP2026-06-30$20.3m1,538,296Unchanged
NEA Management Company, LLC2026-06-30$17.1m1,297,893Unchanged
Venrock Adviser, LLC2026-06-30$13.3m1,009,500Unchanged
Atlas Venture Life Science Advisors, LLC2026-06-30$12.7m962,884Reduced−174,265
Balyasny Asset Management L.P.2026-06-30$12.5m951,783Reduced−88,271
BlackRock, Inc.2026-06-30$10.8m817,621Added+357,615
Affinity Asset Advisors, LLC2026-06-30$9.3m706,904Unchanged
Nantahala Capital Management, LLC2026-06-30$8.7m660,036Unchanged
Nantahala Capital Management, LLC2026-06-30$8.7m660,036Unchanged
ADAGE CAPITAL PARTNERS GP, L.L.C.2026-06-30$7.1m540,968Added+312,568

Recent filings

All 821 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Korro Bio, Inc., recent filings
FiledFormWhat it isAccession number
2026-10-2207:04 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001193125-26-428306
2026-10-0516:10 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001193125-26-414118
2026-08-1916:05 ET8-K8.01 Other events0001193125-26-356877
2026-08-0607:08 ET10-QQuarterly reportPeriod 2026-06-300001193125-26-336707
2026-08-0607:04 ET8-K1.01 Entry into a material agreement; 2.02 Results of operations; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits0001193125-26-336685
2026-08-0417:13 ETSCHEDULE 13D/AOwnership report, active investor, amended0001708269-26-000005
2026-06-1116:42 ET8-K5.07 Shareholder vote results0001193125-26-267741
2026-05-1907:00 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001193125-26-229610
2026-05-0707:08 ET10-QQuarterly reportPeriod 2026-03-310001193125-26-210303
2026-05-0707:04 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001193125-26-210291

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Mar 12, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1703647
Tickers
KRRO
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Non-accelerated filer<br>Smaller reporting company
Former names
Frequency Therapeutics, Inc. (to 2023-11-06)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:32 ET. Listed shows no prices and gives no investment advice.